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ABBREVIATIONS 
APD Automated peritoneal dialysis 
APOL 1 Apolipoprotein L1 gene 
BMI Body mass index 
CI Confidence interval 
CKD Chronic kidney disease 
CAPD Continuous ambulatory peritoneal dialysis 
D/P ratio Dialysis to peritoneal ratio 
ESAs Erythropoetin stimulating agents
ESRD End stage renal disease 
GDP Gross domestic product 
HR Hazard ratio 
HD Haemodialysis 
ISPD International Society of Peritoneal Dialysis 
KDIGO Kidney Disease: Improving Global Outcome 
LMIC Low middle-income countries 
PD Peritoneal dialysis 
PET Peritoneal equilibration test 
Pmp Per million population 
RRT Renal replacement therapy 
RRP Renal replacement programme 
SA South Africa 
SD Standard deviation 
SES Socioeconomic circumstances 




APD Form of PD, where fluid is instilled and drained into the 
abdomen at night via a pre-programmed machine 
CAPD Form of peritoneal dialysis where the patient manually 
exchanges the peritoneal fluid bags (usually every 4 hours), 
throughout the day and in the evening.  
CKD Chronic kidney disease [CKD] is a condition characterized by 
gradual loss of kidney function over time 
ESRD End stage renal disease [ESRD] is a term used to describe 
chronic irreversible renal failure. At this stage renal 
replacement is needed in the form of dialysis or 
transplantation. 
D/P ratio Dialysis to peritoneal ratio – a ratio used to calculate the 
transport status of the peritoneal membrane. 
H = high (>0.81) 
HA =high average (0.65 – 0.8) 
LA low average (0.5 – 0.64) 
L = low (<0.5) 
Gini Coefficient The measure of statistical dispersion intended to represent 
the income distribution of a nation 
HD Is a treatment for patients with end stage renal failure. It is a 
process of purifying the blood. Removing excess solute, fluid 
and waste. 
Kt/V Mathematical equation to describe the clearance of small 
solute urea, as a measure of adequacy. 
PD Is a treatment for patients with end stage renal failure. The 
treatment uses the patient’s peritoneum as a membrane for 
exchange of fluid and solutes from the blood. Removing 
waste and excess fluid. 
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PD-First policy The policy indicates that PD is initiated wherever possible as 
the initial mode of dialysis, unless compelling medical, 
physical or psychosocial factors preclude PD. 
Tenckhoff A soft, flexible indwelling peritoneal catheter, which is inserted 
into the abdomen. It is inserted between the visceral and 
parietal peritoneum in the pelvis. It is used in peritoneal 




1.1 Literature Review of Peritoneal dialysis in Africa and 
PD-First programme in a resource limited setting
1.1.1 Why is CKD a problem? 
Chronic kidney disease [CKD] is a rapidly rising health problem. According to the 
global burden of disease study end stage renal disease [ESRD] as a cause of 
death, has risen from being ranked 27th in 1999 to 18th in 2010.1 The risk of 
developing CKD is described as being “bi-directionally” affected by the level of 
economic development. In high-income countries the high prevalence of 
hypertension, diabetes and obesity are linked to the development of CKD. In low-
income settings risk factors for developing CKD are multifactorial. Low birth weight, 
increase in infectious diseases, ethnic or genetic predisposition (APOL1),2 
unregulated food additives, herbal medications and pollutants are all contributing 
factors3. Poverty itself has been assessed as an independent risk factor for 
microalbuminuria and CKD.4,5  
In low and middle-income countries [LMICs] with rapid urbanization, or places with 
high-income inequalities, such as South Africa [SA], there is an overlap in the 
burden of diseases, with both increased infectious diseases and diseases of 
lifestyle. 
These problems are compounded by the lack of access to health care, medication 
and a limited numbers of nephrologists. In SA in 2009 there were reportedly 1.86 
nephrologists per million population [pmp] as compared to 31 pmp in Western 
Europe. 7 
1.1.2 Dialysis a scarce resource 
In systemic review by Liyanage et al, it is estimated that the number of people 
receiving renal replacement therapy [RRT] will more than double between 2010 and 
2030 to a staggering 5.439 million people.8 To emphasize the extent of the CKD 
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crisis, it is estimated that less than half of all patients who need dialysis receive it.8 
The accessibility to RRT worsens in LMICs where only 7.2% of the global RRT 
recipients reside8. Africa as a continent has the lowest global access to RRT. 
 
In South Africa we have to ration dialysis, due to limitations of access, particularly to 
haemodialysis [HD].  
 
1.1.3 Peritoneal Dialysis-First Rationale 
Peritoneal dialysis [PD]-First programmes aim to initiate patients wherever possible 
on PD as their initial mode of dialysis. Mexico was the first country to adopt this 
policy back in the 1980’s, and remains one of the leading utilisers of PD to date.9,10 
Hong Kong and Thailand have adopted a PD-First policy with a PD favoured policy 
being adopted in Canada, China, India, Spain, Taiwan and the United States.11,12 
This has led to Hong Kong having the highest prevalence of PD in the world at 
72.9%13. Both Hong Kong and Thailand follow a PD-First policy due to cost-
effectiveness.12,13 The success of established PD First-programmes has been 
attributed to numerous factors, including the favourable economics in using PD 
instead of Haemodialysis [HD], reimbursement from medical aids, the education of 
healthcare providers in improving technique related factors, the careful selection of 
patients, anti-PD bias being addressed through education and center 
experience.11,12  
 
In developing countries PD fluid is often imported and the financial cost associated 
with the modality limits its use.6,14 However in SA, PD fluid is produced locally, which 
makes PD a markedly more affordable modality, as compared to the rest of Africa. 
In SA, the cost analysis of PD compared to haemodialysis [HD] is controversial. 
There are varying reports on the cost discrepancy between the two modalities6,14. 
Okpechi et al states that the annual cost per-patient for PD is about 50% of that for 
HD if the PD fluid is manufactured and distributed locally6. At Groote Schuur 
Hospital we have adopted a PD-First policy due to financial feasibility and limited 
accessibility of HD slots.  
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PD remains an attractive alternative to HD.  In our setting it allows for treatment of 
patients from remote areas, decreases travel time for patients (as they do PD at 
home) and lessens disruption to employment or education.  
 
1.1.4 PD in Sub-Saharan Africa 
The SA Renal Registry data from 2015 report that 36% of the patients in the state 
service are maintained on PD15. This accounts for 85% of PD in Africa.14 The 
challenges of practicing PD in SA, include the limited work force, the challenging 
socioeconomic environment16, the higher than accepted rate of peritonitis16 and the 
rationing of dialysis itself. 6,17 However the day to day practicalities of this modality 
are far more complex as PD is often used in households without running water or 
electricity and in informal settlements with communal toilets.  
 
There is a paucity of data on the outcomes of PD programmes in SA and Africa. The 
only outcome based survival data reported in SA on adults, was from Isla et al from 
a PD programme in Limpopo. Their 1-year, 2-year and 5-year survival were 86.7%, 
78.7% and 65.3% respectively with technique survival of 83.3%, 71.7% and 
65.3%18. The predictors of poor outcome were low albumin, being underweight, 
more than one peritonitis event and low haemoglobin.18 The differences between 
the cohort in Limpopo and our Institute are (a) we operate a strict PD-First policy, (b) 
our rationing selection onto renal replacement programme [RRP] is stricter and (c) 
we are a teaching hospital with a dedicated nephrologist who cares for the PD 
patients. Considering that at the time of the study in Limpopo they didn’t have a 
certified nephrologist, their results were very encouraging for practicing PD in 
remote, challenging circumstances.  
 
The role that the socioeconomic status [SES] plays in PD continues to be debated in 
SA and abroad. In 1994 a study from SA described that peritonitis was associated 
with age, black race, room – to –occupant ratio, availability of electricity and informal 
housing, diabetes and several psychological factors.16 However subsequent to this, 
in 2001, Katz, I et al reported no link between socioeconomic status and 
peritonitis.19 A more recent report from Limpopo also failed to demonstrate that SES 
was linked to poor survival or technique success. 18 Internationally, BRAZPD, a PD 
cohort in a country with a similar gross domestic product [GDP] to SA, results 
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demonstrated that economic status was not independently linked to outcomes 20-23 
however in the cohort in Colombia SES was found to influence survival on PD 24 
Whether SES is an obstacle or poor predictive factor for outcome requires further 
investigation.  
 
Data from the rest of Africa is sparse. The only countries to provide low or no cost 
dialysis are reportedly SA, Mauritius and Sudan.14 Only SA and Kenya produce their 
own PD fluid locally.14 There are isolated reports of centers with successful PD 
programmes despite the challenges. Senegal and Egypt reported good peritonitis 
rates for new PD programmes started within in the last 15 years.25,26 However in 
Nigeria the prohibitive personal cost of dialysis results in only 6.8% of the population 
being able to afford treatment for more than 3 months.27 Sudan reported the 
successful initiation of a PD programme, and reported a peritonitis rate of 0.87 
events per patient year.28   
 
1.1.5 The rationale for the Study 
The reason for this MPHIL was to review the outcomes of a PD- First programme 
run in a LMIC with resource constraints. Since PD is a financially viable option in SA 
and the modality is widely used, it is important to know PD programmes success 
and limitations. The aim was to audit our programme to help us understand which 
patients were at greatest risk of adverse events or poor outcomes. Our department 
will use this information to implement measures to address these issues and 
hopefully improve our service. As there is such limited literature on PD in LMIC’s we 
hope that this information will be useful to other countries practicing PD in similar 
settings. 
 
1.1.6 Methodology Aspects 
There were two challenging aspects to the analysis of the methodology. The first 
was describing the adequacy of our dialysis cohort. The conventionally accepted 
way of presenting the adequacy data is reporting Kt/V, which is a mathematical 
equation, related to small solute (urea) clearance. Kt/V was not available for all of 
our patients, as the test was only introduced in our institute in the last 3 years of the 
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study. The second was the lack of standardized definitions used to describe PD 
dialysis technique failure. 
 
Adequacy of PD is internationally reported as Kt/V with an accepted goal of a Kt/V 
of 1.7. However the ISPD guidelines state that: ‘adequacy should be interpreted 
clinically rather than by targeting only solute and fluid removal. Clinical assessment 
should include clinical and laboratory results, peritoneal and renal clearance, 
hydration status, appetite and nutritional status, energy level, haemoglobin 
concentration, responsiveness to erythropoietin therapy, electrolyte status and blood 
pressure.’29 Reporting these clinical variables was challenging as they were 
recorded at multiple visits.  
 
In the absence of a validated score we opted to use the assessment tool of 
Fresenius dialysis units worldwide. The tool utilizes clinical variables to assess 
adequacy. The target ranges for the clinical variables were determined by the 
KDIGO guidelines. The scoring system describes the amount of time a patient 
meets the clinical target, and divides them into three groups i.e. never, 0 -<50% of 
the time, >50% of the time. The KDIGO target ranges for these clinical variables 
include fluid status of euvolaemia, calcium and phosphate within the physiological 
ranges (calcium 2.1 – 2.5mmol/L, phosphate <1.5mmol/L), haemoglobin between 
9.5 – 11g/dL.30 Urea (<21mmol/L) represents small solute clearance. Due to the 
small number of malnourished people in our cohort we set the cut off for acceptable 
urea at less than 21mmol/L.  
 
The second difficulty was in describing PD technical failure. There is a lack of 
uniformity in the definitions used to define technique failure in different PD 
registries.31 The PDOPPS study that is currently underway, aims to standardize the 
PD related practice definitions.31 We have therefore used the definition set out by 
the PDOPPS to define our cohorts technique failure; “any PD related complication 
that leads to the permanent cessation of the therapy.” 31 For our technique failure 
we included all patients who underwent modality switch from PD to HD and those 
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1.2 Ethical considerations 
Before the study commenced and data was collected, research ethics approval for 
the project was received from the Faculty of Health Sciences Human Research 
Committee. Approval number Ref no: R007/2014.  
(Ethics approval for the study – see Appendix 2) 
 
The most important ethical consideration in this study was patient confidentiality. 
The data was collected through a folder review. The retrospective information was 
confidentially collected by a review of the information already present within the 
patients’ folders. The patients’ clinic visits and routine laboratory investigations were 
not altered and the study followed the best clinical practice guidelines set out by 
KDIGO. As this was a retrospective folder review, informed consent was waived. 
 
Patient confidentiality was maintained by storing all of the information from the 
patients’ folders, under the unique folder number in the registry. This registry was 
only accessible via a unique coded password, known only to the investigators. The 
data was stored on a password locked computer. This was in keeping with the 
declaration of Helsinki 2013. 
 
The benefit and social value of this study will be in identifying high-risk sub 
populations within our PD cohort. The information will be used to address sub-
optimal therapy/management to improve patient outcomes in a resource-




1.3 Why was PDI chosen – Authors considerations 
 
I have chosen PDI [Peritoneal dialysis International] as my journal of choice for 
submission for publication. It is a very respected journal in the field of peritoneal 
dialysis. 
 
PDI has an impact factor of 1.527. It is indexed in major databases used for 
research (MEDLINE, PUBMED, Science Citation Index). It has a broad reach as it is 
accessed from over 160 countries, by over 30000 people annually.  
 
The Author has the option for open access and there are no author fees attached. 
Articles are widely promoted by email, social media and newsletter. 
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South Africa [SA] currently performs the most peritoneal dialysis [PD] in Africa. Yet, 
outcome data is limited. With the collision of epidemics of communicable and non-
communicable diseases in Africa the need for chronic dialysis is escalating. PD 
remains a life-saving modality especially as haemodialysis is limited in the state 
sector.  
Methods:  
We retrospectively analysed all patients undergoing PD at Groote Schuur Hospital 
from January 2008 until June 2014 and thereafter prospectively until June 2015. 
Variables included demographics, adequacy, modality, fluid, cardiovascular risk and 
diabetes. The influences of these variables on peritonitis rate, technique and patient 
survival were assessed.  
Results:  
230 patients were initiated on PD, 31 were excluded as they were on PD for < 90 
days. The mean age was 39.7 +/- 10.4 years [SD], 49.8% were male and 63.8% 
were mixed ancestry. 9.8 % were diabetic at dialysis initiation. The average length 
of time on PD was 17 months (IQR 8 – 32). The peritonitis rate was 0.87 events per 
patient years. One, 2 and 5 year patient and technique survival was 94.4%, 84.3% 
and 60.2% and 82.5%, 69.0% and 37.4% respectively. Fluid overload (p=0.019) and 
low haemoglobin (p=0.001) were independent risk factors for poor survival.  African 
race (HR 1.97, 95% CI (1.16 – 3.37) and fluid overload (p= 0.002) were both 
predictors of technique failure. 
Conclusions:  
In our PD-First programme the results are encouraging, despite lack of home visits 
due to safety, resource limitations and a high disease burden. Technique failure in 
African race needs further evaluation. Peritoneal dialysis remains a viable, life-
saving alternative in an African setting.  
Key words: 




2.3 Introduction  
South Africa [SA] is a country at the southern tip of Sub-Saharan Africa [SSA], with 
a population of 53 million.1 It has the highest income inequality in the world with a 
Gini coefficient of 63.4.2 In SSA, over half the population lives on less than 1$ per 
day, and yearly per capita expenditure on health ranges from $9 – $158 compared 
to over $2000 in Europe.3  
 
Chronic Kidney disease [CKD] prevalence is rising worldwide. In SA our high-
income inequality is driving a dual epidemic of communicable4 and non-
communicable diseases5. This is further illustrated by Jha et al, which reports that 
people living in the lowest socio-economic quartile are at a 60% greater risk of 
progressive CKD.6 Additional contributing factors include low birth weight7, ethnic or 
genetic predisposition 8  traditional medications4 and poverty itself.6,9 Lack of access 
to essential medication is also a contributory factor. 
 
Despite the rise in CKD, access to renal replacement therapy [RRT] in low and 
middle-income countries [LMICs] remains limited.10 Only 7.2% of the global 
prevalence of RRT is reported to occur in these regions, and over half of those that 
need RRT do not have access.11 In Africa the situation is far worse with only 16% of 
patients receiving RRT.11 This situation is exacerbated by a scarcity of specialists. In 
2009 there were only 1.8 nephrologists per million population [pmp] in SA,3 
compared to 31 pmp in Western Europe and 22 pmp in Northern America.12  
 
SA performs 85% of the peritoneal dialysis [PD] in Africa, 13 of which 36% is 
performed in state sector hospitals for patients without medical insurance.14 PD has 
the advantage of allowing patients from areas remote to a dialysis centre to receive 
treatment, but with high rates of poverty, unemployment and resource constraints in 
SA, PD has a unique set of challenges.  
 
The study was performed in a state sector hospital in the Western Cape [WC] 
Province. The province has an estimated population of 6,362,257 million, with a 
racial breakdown of 48.8% mixed ancestry; Africans and Caucasians constitute 
32.9%% and 15.7% respectively.15,16 74.8% of the province’s population is 
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estimated to be uninsured and therefore relies on state medical care.15 The WC has 
the highest prevalence of patients accessing RRT in SA [312 pmp], with the state 
only accounting for 14.7% of these facilities.14  
 
Groote Schuur Hospital [GSH] is one of 4 adult state facilities in the province 
offering dialysis. The hospital provides tertiary medical care to 42% of the WC 
population i.e. 2.67 million, and transplant and clinical outreach support to a further 
10%.15 State chronic medical care including dialysis is free for those who can’t 
afford it, however due to the expense of RRT, dialysis is rationed. The rationing 
process is ethically endorsed and strictly adhered to.  
 
The selection criteria for acceptance onto the renal replacement programme [RRP] 
are based on suitability for transplantation. A committee meeting is held weekly to 
review patients for suitability for our programme. The committee panel is comprised 
of nephrologists, physicians, hospital management and social workers. Despite the 
large drainage population Groote Schuur Renal Unit only accommodates 148 
patients for chronic dialysis, 98 for haemodialysis [HD] and 50 for PD. Due to the 
limitation of access to dialysis and in particular haemodialysis [HD] slots our policy is 
to promote a PD-First programme. All patients suitable for PD are initiated on PD 
unless compelling medical, physical or psychosocial factors preclude the use of PD.  
 
The PD-First programme is run by two qualified PD trained sisters. Patient training 
is undertaken by the PD sisters, in a 2-week intensive, one-to-one basis. Retraining 
is performed if recurrent peritonitis occurs. All patients have a straight double cuff 
Tenckhoff catheter inserted by a nephrologist or surgeon. Continuous ambulatory 
peritoneal dialysis [CAPD] via twin bag, flush-before-fill system is used. A limited 
number of patients have access to Automated Peritoneal Dialysis [APD] i.e. if 
working or young adults studying. A nephrologist initially reviews all the patients 
monthly. Adolescents continue to be seen monthly, while adults are reviewed 3 
monthly if clinically stable. This follows the guidelines as set out by the Kidney 
Disease: Improving Global Outcomes [KDIGO]. 17 Our PD-First programme does not 
cater for home visits due to staff safety concerns, and is limited by the availability of 
only glucose-based PD solutions. 
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To date there is very little information reporting outcomes on PD-First programmes 
in LMICs.10 Therefore this study aimed to evaluate the success of our programme in 
a resource limited setting and identify factors linked to poor outcome.  
 
2.4 Methods 
The data was collected at Groote Schuur Hospital retrospectively from 2008 to June 
2014, then prospectively until June 2015. All patients starting dialysis in this time 
period and surviving at least 3 months on the initial dialysis modality were included. 
The baseline demographics, cause of end stage renal disease [ESRD], biochemistry 
and cardiovascular risk were documented.  
 
Laboratory investigations and clinical examinations were performed as 
recommended by the KDIGO guidelines.17 Peritoneal equilibration test [PET] tests 
and Kt/V were only routinely available and performed in the last 3 years of the study. 
The initial PET including Kt/V was performed at six weeks post CAPD initiation. It 
was only repeated when clinically indicated. Transporter status was defined by the 
use of a dialysis- to- plasma [D/P] creatinine ratio. High transporter status was 
(H:>0.81), high average (HA; 0.65-0.8), low average (LA; 0.5 – 0.64) and low 
transporter (L; <0.5).18  
 
In the absence of a validated scoring system of reporting clinical variables as a 
reflection of adequate dialysis, we based our scoring system on those used by 
Fresenius dialysis units worldwide. In a resource limited setting with limited access 
to Kt/v this scoring system is a pragmatic approach to determine how well a patient 
is being dialysed. This scoring system reflects how often an individual reaches the 
KDIGO targets. Targets were set for euvolaemia, phosphate (<1.5mmol/L), calcium 
(2.1 – 2.5mmol/L), haemoglobin [Hb] (9.5 – 11g/dL) and urea (<21 mmol/L). We 
subdivided these targets into 3 categories: never achieved, achieved >0% but < 
50% or ≥ 50% of the time. Euvolaemia was determined clinically on routine follow up 
by nephrologists, where clinical parameters including elevated JVP, pedal oedema 
and clinical evidence of pulmonary oedema were assessed. Fluid overload was 
defined as not meeting targeted euvolaemia in > 50% of the patients clinical visits.  
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Technique failure was defined as “any PD related complication that leads to the 
permanent cessation of the therapy”.19 This included peritonitis (refractory), 
inadequate dialysis, catheter malfunction, leak or patient related reason (not 
coping), ultrafiltration failure, and death from any PD related cause. Peritonitis and 
its sub categories of recurrent, relapsing, repeat, refractory and catheter related 
peritonitis as well as exit site infection were defined using the ISPD guidelines.20 
Mortality data was obtained from patient folders, death certificates, clinic records 
and patient families. Fluid overload as a cause of death was defined as clinical fluid 
overload at the time of death with pulmonary oedema.  
 
All statistical analysis was performed using Stata (Version 13.1; Stata Corp, College 
Station, Texas, USA).  Descriptive statistics were used to present the patient’s 
demographic and clinical characteristics. Continuous variables were presented as 
means (± standard deviation [SD]) or medians (with interquartile range [IQR]), while 
categorical variables were presented as frequencies and percentages. For 
comparison of categorical variables Chi-squared or Fishers exact test were applied, 
while comparison of continuous variables between groups were compared using 
Students t-test or Wilcoxon Rank Sum test. 
 
Using death or technique failure as the primary end points, survival probabilities 
were analyzed using Kaplan-Meier method and hazard ratios were estimated using 
Cox proportional hazard regression. For analysis examining time to patient death, 
patients were censored for renal transplantation, patient relocation, transfer off PD 
programme or remaining on PD at the end of the observation period (30th June 
2015). Patients who were no longer transplantable and not offered modality switch 
from PD to HD, were also censored. For technique survival, patients were censored 
at their date of renal transplantation or remaining on PD at completion of the study 
(30th June 2015). Respective risk factors associated with death and technique failure 
were first assessed using univariate Cox regression for all baseline characteristics 
including biochemical variables and urine output. Number of peritonitis events, 
transporter status, and assessment of the percentage of times a patient met 
adequacy targets (defined above) were included as covariates in the regression. 
Variables were retained in the multivariable model if they had p<0.25 in univariate 
analysis. Age, race, gender, diabetes and more than 1 peritonitis event were added 
into the model as they were clinically relevant regardless of statistical contribution. 
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For effect size measures, both unadjusted and adjusted hazard ratios [HRs] were 
presented with 95% confidence intervals [CI]. P-values <0.05 were considered 
statistically significant.  
2.5 Results 
The study included 199 patients, of whom 99 (49.8%) were male (Table 1). Mixed 
ancestry was the most common ethnic group, in 63.8% of cases. The median length 
of time on PD was 17 months. At baseline our patients had a low cardiovascular risk 
profile with only 19 (9,8%) being diabetic and 34 (17,5%) smoking. Nutritional status 
at baseline showed a small proportion of patients having a low body mass index 
[BMI] (<18.5kg/m2), with 3.6% being underweight and only 6 patients having an 
albumin less than 30g/L.   
The peritonitis rate was 0.87 peritonitis events per patient year. 47.5% of the 
organisms isolated were gram-positive, 3.96% had pseudomonas and 5.0% fungal 
peritonitis (Supplemental figure 1). Our culture negative rate (19.5%) met ISPD 
standards of less than 20%.  The percentage of patients that had one event was 
22.6%, 2 events 15.1% and 23,3% had 3 or more events. 
Figure 1 reflects the adequacy as represented by biochemical and clinical 
parameters at 6 months, 1 and 2-year time points. Phosphate and urea targets were 
not achieved more that 50% of the time. Approximately half of patients reached 
targets for fluid control and haemoglobin.  
2.5.1 Patient survival 
Our patient survival probability at 1, 2 and 5 years was 94,4%, 84,3% and 60,2% 
respectively. (Supplemental figure 2) Overall 32 patients died.  The most common 
cause of death was fluid overload (37.5%), followed by infection with no direct 
relationship to PD (18.8%), infection related to PD (12.5%), malignancy (12.5%), 
sudden death (9.4%) and miscellaneous (9.4%) (Supplemental table 1). Of those 
dying from fluid overload, 5 (41.7%) were diabetic and 12 (100%) were HA 
transporters and only 1 patient had a residual urine output of less than 250ml at 
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baseline. Of the 32 patients that died 12 were not eligible for modality switch, as 
they were no longer considered transplant candidates.  
Univariate and multivariate analysis of risk factors associated with increased risk of 
patient death are described in table 2. Independent risk factors for poor survival 
were 1) not reaching target for haemoglobin [Hb] and 2) fluid overload. Achieving 
target ranges more than 50% of the time for fluid and haemoglobin reduced the 
hazard ratio for death by 76% for each variable respectively. Patients with diabetes 
had nearly 3 times increased risk of death.  
2.5.2 Technique survival 
Technique survival at 1, 2 and 5 years was 82.5%, 69.0% and 37.4% respectively. 
(Supplemental figure 2) For those requiring modality switch the commonest cause 
was peritonitis (50%). Fungal peritonitis accounted for 38.5% of these events. 
Alternative causes of technique failure were catheter malfunction (24.1%), 
inadequate or failed PD (14.8%), patient not coping with PD (7.4%) and leak (3.7%). 
The independent risk factors for poor technique survival were African race (HR 1.97, 
95% CI 1.16 – 3.37), and fluid overload (HR 0.30, 95% CI 0.14 – 0.64) (Table 3). 
Patients reaching euvolaemia less than 50% of the time were 70% less likely to 
have technique failure compared to those never achieving euvolaemia. Among 
patients of African ethnicity, 42.2% experienced technique failure, and the reasons 
were peritonitis in 42% (n=10), catheter malfunction in 29% (n=7), inadequate 
dialysis in 21% (n=5) and leak in 8% (n=2).   
2.6 Discussion 
In the state sector in South Africa chronic medical care including dialysis is provided 
for free for indigent patients, for those receiving a disability grant or state pension. 
Due to financial constraints dialysis is rationed, via an ethically endorsed selection 
criteria. This selection process favours younger, fitter, healthier patients as suitability 
for transplantation is the guiding principle to optimise use of scarce dialysis slots.21 
As a result, our cohort differs from other PD studies. This is evident when comparing 
our results with countries that don’t ration dialysis and have a similar gross domestic 
29 
product (GDP), i.e. Mexico, Brazil and Columbia. The average age was 16 – 18 
years younger than those in Brazil and Columbia, 22,23 there were strikingly less 
diabetics (9.8% vs. 20 – 44%) than in the other cohorts,22-24 and fewer patients had 
documented cardiovascular disease (Table 4). The differences in our cohort were 
further evident when reviewing causes of death. Cardiovascular death and 
infections are the two most common causes of death in PD registry data.25 However 
when reviewing our causes of death, fluid overload was the most common cause 
followed by infection. Only 50% of those dying from infection had an infection 
related to PD itself.  
Patient survival is not inferior to countries with similar GDP, other PD-First 
programmes or developed countries reporting PD registry data. This can be partially 
attributed to the selection criteria used, but the results would have been significantly 
better if transfer to haemodialysis could be guaranteed in all cases. However 
survival rates were good considering that 12 of the 32 patients that died (37.5%) 
were no longer transplantable and hence not offered a switch to haemodialysis.  
The independent risk factors in our cohort that were linked to poor survival were 
fluid overload and not meeting target for haemoglobin. The finding that fluid 
overload accounted for 37.5% of deaths in the absence of cardiovascular disease 
was one of the major findings in this observational study. This was not related to 
loss of residual renal function [RRF]. A high transporter status was identified in all of 
the patients with fluid overload and half were diabetic. It has highlighted the 
importance of PD fluid and modality choice. Over hydration in PD, has been found 
to be a predictor of mortality, independent of cardiac failure.30 Icodextrin is effective 
at increasing ultrafiltration without impairing residual renal function.31 APD has also 
been shown to improve survival in high transporters,32 and in anuric patients.33 
Unfortunately due to cost constraints our PD programme has limited APD and no 
access to icodextrin. Motivation to the health authorities for selected availability of 
icodextrin is a possible option in the setting of ultrafiltration failure.  
9.8% of the cohort was diabetic, with relatively little comorbidity. However this group 
still had a nearly threefold increased risk of death. On multivariate analysis this 
approached statistical significance with 95% CI of 0.95 – 8.36 and a p value of 
0.062. Studies have shown that predictors of long-term survival in diabetic patients 
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on PD are age, pre-dialysis comorbidity, RRF, adequate nutrition, transporter status 
and peritonitis.34-36 Our diabetic cohort was young, well nourished and the majority 
had good RRF.  Despite this they still had a worse survival, likely due poor diabetic 
control (57% had an HBA1C >8) and HA transport status (100%).  
A low haemoglobin in CKD is associated with poor cardiovascular outcomes due to 
left ventricular hypertrophy and worsening ischaemia.37 Not reaching KDIGO target 
for haemoglobin was an independent predictor of poor outcome in our cohort. 
Anaemia as a poor predictive marker was similarly found in a diabetic cohort in 
China38, in BRAZPD39  and locally in Limpopo.40 Erythropoetin stimulating agents 
[ESAs] were previously only available to employed patients. By 2010 all patients 
had access to Recormon. Recormon was the only available ESA at Groote Schuur 
during the study period. Currently, due to cost constraints, we are only able to start 
Recormon when patients commence dialysis. Furthermore, patients often present 
very late requiring dialysis at presentation. As the majority of our patients were well 
nourished at baseline we postulate that the likely cause of anaemia in our cohort 
may be linked to inflammation and inadequate dialysis. Therefore this may be an 
epiphenomenon.  
Being underweight, malnourished and a low albumin have been shown to confer 
worse survival for patients on PD.25,41 In SA, Isla et al described that low albumin 
and low BMI were linked to death or technique failure in their PD cohort in 
Limpopo.40 Our cohort had a low prevalence of being underweight (i.e. BMI 
<18kg/m2) at baseline (3.6%), and a good mean baseline albumin of 38.7g/dL. 
Despite very few of our patients being underweight a low BMI did convey a 3.27 
times increased risk of death. For every 1g/L increase in albumin, the risk of death 
decreased by 3%. Our survival data reflects the ‘obesity paradox’ as being obese 
conveyed a 17% decreased relative risk of death. 
Factors associated with technique failure include age, center experience, distance 
from center, socioeconomic factors, initial PD modality, diabetes, low albumin and 
peritonitis.22-24,42 The two commonest reasons for technique failure in our cohort 
were peritonitis and catheter malfunction.42 However on univariate and multivariate 
analysis only African ethnicity and fluid overload were associated with poor 
technique survival. African ethnicity in our population is a surrogate marker for 
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poorer socioeconomic status due to our history of discrimination against Africans 
resulting in profound income inequalities. The reason for Africans having worse 
technique survival is however not clear. On subgroup analysis recurrent peritonitis 
events were not greater in Africans compared with non-Africans, 39% and 37.8% 
respectively. The impact of socioeconomic status [SES] on technique survival 
remains debated. In SA, Lent et al (1994) showed that poorer SES was associated 
with peritonitis.43 However since this study, newer PD techniques (flush-before-fill) 
have shown decreased peritonitis rates. A local study from Limpopo and the 
BRAZPD cohort did not demonstrate an association between family income, SES 
and technique failure.40,44 Further investigation is required to ascertain why the 
African subgroup is at an increased risk for technique failure. This is an area in PD 
that needs clarification in Africa, as room occupancy, running water, electricity and 
sanitation are still taken into account in our PD-First programme when deciding on 
modality.  
In our PD programme young adults <25 years are offered APD to complete 
schooling and studies. Young adults have been reported in the literature as a high-
risk group for technique failure. However only 15% of our young adults experienced 
technique failure in the subgroup analysis.  
Despite the social challenges the peritonitis rate for our unit was 0.87 episodes per 
patient year. This is higher than the recommended ISPD standard of 0.67.20 Our unit 
has shown a steady decline in our peritonitis rate over the last 15 years. In 1994 the 
units peritonitis rate was 2.7 43 and it had declined to 1.7 episodes per patient year 
in 2002.3 (Supplemental figure 3b) We attribute this steady decline to newer PD 
technique, better patient care and education.  
Due to the lack of availability of Kt/V, surrogate biochemical and clinical markers for 
overall small solute clearance, patient wellbeing and dialysis adequacy were 
obtained. This included bone mineral health, Hb, nutrition, urea and fluid control. 
Patients who never met the KDIGO targets for these variables had a statistically 
significant increased chance of death. Phosphate control was particularly poor, but 
access to phosphate binders is generally limited to calcium carbonate due to 
resource constraints. 
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Limitations of this study included firstly, partial retrospective study design and limited 
Kt/V analysis due to the test only being instituted in the last 3 years of the study. 
Secondly, no socioeconomic information was collected. This will be important to 
look at in the future to understand why our African cohort had worse technique 
survival. Thirdly, there are a limited number of HIV infected patients in our cohort. 
This is a reflection of the selection criteria for renal replacement endorsed by the 
Western Cape. Not all provinces select patients in this manner. Therefore it is 
important to note the lower number of HIV positive patients in our cohort compared 
to dialysis programs in other parts of SA.45 Lastly for statistical modeling a mixed-
effect modeling technique could also be considered in measuring the effects of 
repeated laboratory measures on other outcomes. However this analysis would be 
challenging given the proportion of missing laboratory data from 1 year of follow up. 
Competing risks analysis in survival modeling for nephrology specific outcomes will 
be used to produce more reliable adjusted effects for HRs in future analysis.   
2.7 Conclusion 
This study shows that a PD-First programme can be successfully offered in a 
resource limited setting.  Even without home visits, limited APD and resource 
constraints limiting icodextrin use. Our results are comparable to larger cohorts, 
registries in similar GDP brackets and in PD programmes within higher income 
countries. This is likely to be attributed to the selection criteria that we use in 
rationing our dialysis, thereby selecting patients who are suitable for transplantation. 
Being fluid overloaded, diabetic and having low haemoglobin are linked to poor 
survival. These areas need to be targeted, with possibly selected use of icodextrin 
and APD. When the success of a programme and access to RRT relies on 
transplantation and turnover, understanding poor predictive factors and aggressively 
addressing them is vital for success. Our data supports the use of PD-First 
programme in South Africa, as it is a life-saving modality in a continent where RRT 
is scarce.  
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Dialysis in Patients with HIV and End-Stage Renal Failure. Perit Dial Int 
37, 321-330, doi:10.3747/pdi.2016.00165 (2017). 
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2.9 Tables: 
Table 1: Baseline characteristics of our PD cohort 
All patients (n=199) 
Age (years) Mean +/- SD 39.65 +/- 10.35 
Age:     14 – 24yrs n (%) 19 (9.6) 
25 – 44 yrs. n (%) 110 (55.3) 
45 – 60 yrs. n (%) 70 (35.2) 
Males 99 (49.8) 
Race:   African n (%) 64 (32.2) 
Mixed Ancestry n (%) 127 (63.8) 
White n (%) 8 (4.0) 
Time on PD (months) Mdn (IQR) 17 (8 – 102) 
Mode of dialysis: CAPD n (%) 181 (92.3) 
Primary renal disease 
Hypertension n (%) 64 (33) 
Chronic Glomerulonephritis n (%) 79 (40.7) 
Diabetes n (%) 14 (7.2) 
HIVAN n (%) 2 (1) 
Urological n (%) 10 (5.2) 
Other n (%) 25(12.9) 
Baseline albumin Mean +/- SD 38.7 (+/- 5.4) 
Reason for PD: 
PD-First n (%) 170 (89.9) 
Lack of vascular access* n (%) 8 (4.0) 
Failed Transplant n (%) 12 (6.0) 
Diabetes n (%) 19 (9.8) 
HbA1C >8 n (%) 9 (52.9) 
BMI 
Overweight and obese n (%) 98 (50.5) 
Underweight n (%) 7 (3.6) 
Uncontrolled Hypertension n (%) 141 (73.4) 
Smoker n (%) 34 (17.5) 
Smoke > 10 pack yrs. n (%) 13 (38.2) 
HIV n (%) 6 (3.0) 
Chronic Hepatitis B n (%) 4 (2.0) 
Coronary artery disease at baseline** n (%) 7 (3.6) 
*Lack of Vascular Access = patients transferred from HD to PD as they no longer
have sufficient vascular access for HD. **(Symptomatic with, or on treatment for
ischaemic heart disease. Proven on ECG or angiogram) BMI = body mass index,
HIV = human immunodeficiency virus, HIVAN= human immunodeficiency virus
associated nephropathy
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Table 2: Factors significantly associated with increased risk of 
patient death.  
Univariate Multivariate 
HR (95% CI) P 
value 
HR (95% CI) P 
value 
Age (>40) 0.98 (0.48 – 2.03) 0.961 1.70 (0.69 – 4.15) 0.247 
Gender (male) 1.51 (0.74 – 3.09) 0.262 1.65 (0.67 – 4.06) 0.273 
Race (African) 1.21 (0.55 – 2.68) 0.638 0.56 (0.20 – 1.59) 0.278 
Albumin (per g/L) 0.97 (0.91 – 1.04) 0.410 0.98 (0.91 – 1.07) 0.703 
Diabetes 2.93 (1.17 – 7.33) 0.021 2.82 (0.95 – 8.36) 0.062 
BMI 
     Underweight (<18.5) 4.44 (0.95 – 20.67) 0.057 2.09 (0.35 – 12.32) 0.418 
     Overweight (30–34.9) 1.54 (0.69 – 3.46) 0.293 1.26 (0.53 – 3.01) 0.597 
     Obese (>35) 0.63 (0.17 – 2.39) 0.500 0.83 (0.16 – 4.19) 0.819 
Urea target (ref: never met 
target) 
      Met target range <50% 0.31 (0.10 – 0.96) 0.042 0.27 (0.07 – 1.02) 0.055 
      Met target range >50% 0.42 (0.19 - 0.90) 0.026 0.80 (0.26 – 2.47) 0.695 
Fluid targets (ref: never 
met target) 
      Met target range <50% 0.19 (0.07 – 0.54) 0.002 0.22 (0.07 - 0.78) 0.019 
      Met target range >50% 0.20 (0.09 – 0.46) 0.000 0.24 (0.07 – 0.79) 0.019 
Haemoglobin (ref: never 
met target) 
      Met target range <50% 0.10 (0.02 – 0.46) 0.003 0.05 (0.01 – 0.31) 0.001 
      Met target range >50% 0.37 (0.17 – 0.81) 0.012 0.24 (0.09 - 0.69) 0.008 
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Table 3: Univariate and multivariate factors associated with 
technique failure 
Univariate Multivariate 
HR (95% CI) P value HR (95% CI) P value 
Age (>40) 1.06 (0.65 – 1.72) 0.811 1.39 (0.82– 2.34) 0.220 
Gender (male) 1.24 (0.76 – 2.00) 0.392 1.28 (0.76 – 2.16) 0.359 
Race (African) 1.78 (1.07 – 2.92) 0.024 1.98 (1.16 – 3.37) 0.013 
Albumin (per g/L) 0.98 (0.93 – 1.01) 0.270 0.98 (0.93 – 1.03) 0.387 
Peritonitis > 1 event 0.98 (0.60 – 1.58) 0.925 0.99 (0.59 – 1.66) 0.964 
Diabetes 1.78 (0.87 – 3.63) 0.110 1.74 (0.82 – 3.70) 0.147 
BMI 
     Underweight 1.35 (0.32 – 5.72) 0.681 0.74 (0.16 – 3.50) 0.704 
     Overweight 1.12 (0.66 – 1.92) 0.668 1.03 (0.59 – 1.82) 0.906 
     Obese 1.01 (0.49 – 2.05) 0.985 1.23 (0.58 – 2.61) 0.581 
Fluid targets (ref: never 
met target) 
    Met target range <50% 0.32 (0.16 – 0.65) 0.002 0.30 (0.14 – 0.64) 0.002 
    Met target range >50% 0.38 (0.22 – 0.67) 0.001 0.39 (0.21 – 0.72) 0.003 
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Table 4: Comparing PD cohort’s survival from different countries
Patient Survival 






















26 2009 - 2011 56327,72 - 33 94 - 77 61 
Hong Kong
27 1995 - 2009 42422,87 59.2 46 91.1 - 69.6 50.7 
New Zealand 
26 2009 – 2011 37807,97 - 43 94 - 71 49 
Mexico 
24 2007 9009,26 - - 90 78 72 - 
Romania 
28 1995 - 2001 8972,92 49.5 23 90.6 62.2 
Brazil (BRAZPD2) 
22
2004 - 2011 8538,59 59.5 41 85 74 64 48 
Columbia 
23 2008 - 2009 6056,15 54 34 92.4
5 
81.5 - - 
Thailand 
29 2008 - 2011 5775.10 - -. 79 66 - 57 
South Africa 2008 - 2015 5691,69 39 9.8 94.4 84.3 - 60.2 
42 
2.10 Figures: 
Figure 1: Achieved adequacy targets at 6 months, 1 year and 2 
year  
Figure one reflects the total percentage of patients achieving KDIGO set targets for 













2.11 Supplementary figures and tables 
Supplemental Figure 1: Organisms cultured during peritonitis 
episodes  
Supplemental Figure 1 reflects the organisms cultured in peritonitis events as 
reflected as percentage of the total. The group of peritonitis labeled Other 
comprises: Gram-positive species other (87.5%), TB (6.3%) and multiple organisms 
(6.3%). The group Gram Negative comprises: Gram Negative other (43.4%), 














Supplemental Figure 2: Kaplan-Meier of patient and technique 
survival 
Supplemental figure 2: A) Kaplan-Meier survival curves for patient survival. B) 
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Patient survival on PDA B
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Supplemental Figure 3a): Peritonitis episodes per year as 
reflected by individual organisms 
Supplemental Figure 3a) reflects the number of peritonitis episode for each 
















Supplemental Figure 3b): Decreasing Peritonitis Rate at Groote 
Schuur Hospital over the last 20 years
Supplemental Figure 3b) reflects the decreasing trend of peritonitis episodes per 
































Supplemental Table 1: Causes of death in PD cohort 
Cause of Death N = 32 % 
Fluid overload 12 37.5 
Infection – no relation to PD 6 18.8 
Infection – related to PD 4 12.5 
Malignancy related 4 12.5 
Sudden Death 3 9.4 
Trauma 1 3.1 
CVA 1 3.1 
Unknown 1 3.1 
Supplemental Table 1 reflecting causes of death for 32 patients. Reflected as 
number of deaths and percentage. 
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Appendix 1: Data capture sheet for Peritoneal 
Dialysis database 
Patient Profile: 
Surname:     Folder No:  Sex (M/F) 
Initial:   D. O. B: DD/MM/YY
Start date of PD: DD/MM/YY 
Initial / baseline Profile: 
Date of baseline: DD/MM/YY 
Reason for PD: 
 PD First
 Out of vascular access for HD
 Failed transplant
 Patient preference













Family history of Coronary artery disease (Y/N) 
Patient: Weight          (kg)   Height   (m) BMI   (kg/m2)    Waist circumference    
(cm) 
Previous transplant (Y/N)    Number of previous transplants. 
BP >140/90   (Y/N) 
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 Developed HIV on PD
Hepatitis B: 
 Negative
 Chronic hepatitis B prior to PD
 Chronic hepatitis B on PD
Smoker: 
 Yes – currently




 1-5 packs/ year
 5 – 10 packs/ year
 10 – 15 packs/ year
 >15 packs/ year








Corrected Calcium (mmol/L) 
50 
Phosphate    (mmol/L)      
Calcium/ Phosphate product               . 
Albumin (g/L) 
Uric Acid (mmol/L) 
Creatinine  (umol/L) 
Total cholesterol (mmol/L) 
LDL cholesterol  (mmol/L) 
Lateral abdominal x-ray score (   /24) 
Dialysis Adequacy: (documented yearly) 
Date of recorded visit: DD/MM/YY 
Concern of compliance  (Y/N) 
Mode of dialysis: 
 CAPD
 APD
 Change from CAPD – APD
 Change from APD – CAPD
Dialysis Fluid (number of each glucose containing concentration of bags) 
 1.5% Glucose bags  (number) 
 2.5% Glucose bags  (number) 









Ferritin:  (ug/L) 
Corrected Calcium: (mmol/L) 
Phosphate: (mmol/L)      
Calcium/ Phosphate product               . 
PTH: (pmol/L)         Parathyroidectomy (Y/N)  
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Magnesium: (mmol/L)    
Albumin: (g/L) 






 Urine volume (ml) 
 RRF (ml/min) 
 Cr Clearance  Urine (ml/min) 
 Cr Clearance PD (ml/min) 
 Total Creatinine Clearance     (ml/min) 
 Kt/V (ml/min) 





















 Catheter related infection
Catheter Malfunction: 
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o No antibiotics required
o Infection requires antibiotics
o PD antibiotics
o Systemic antibiotics
o Requires catheter change
 Requires catheter change: Y/N
Malnutrition and Cardiovascular risk: 
 Weight (kg) 
 Height  (m) 
 BMI  (kg/m2) 
 Waist circumference  (cm)










 Yes – currently




 1-5 packs/ year
 5 – 10 packs/ year
 10 – 15 packs/ year
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 >15 packs/ year







 Uric acid: (mmol/L) 
 Cholesterol total: (mmol/L) 
 Cholesterol LDL: (mmol/L) 
 Creatinine: (umol/L) 
Outcome 
Adequate dialysis: (Y/N) 
Death 
Date of death: (DD/MM/YY) 




 Infection – related to PD







 Date of transplant: DD/MM/YY
Permanent transfer to HD: 
 (Y/N)
 Date of transfer: DD/MM/YY





o Patient not coping
Patient removed off PD programme: 
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 Date removed: (DD/MM/YY)
 Reason off removed off PD:
o Lost to follow up
o Contract terminated
o Move to private
o Relocated
o Patient not coping
o Regain renal function
Required rest on HD 




TB during course of PD 





Still on PD: 
 (Y/N)
 Date of last follow up: DD/MM/YY
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Appendix 2: Ethics approval 
signature removed
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Appendix 3: Instructions to the author set out 
by PDI for original work 
Original Article instructions to the Author 
 Peer reviewed investigations that represent new and significant contributions
to the field.
 Maximum length 3500 words excluding abstract and references;
 40 references;
 5 figures and tables;
 Abstract maximum 250 words presented as background, methods, results
and conclusion.
 Content can be supplemented with online only material to be formatted by
the author and uploaded with the article using the appropriate template.
Where methodology is particularly extensive, more detailed information
should be provided in the online only supplemental material. The main text of
the paper must stand on its own without the supplemental material.
MANUSCRIPT PREPARATION 
Peritoneal Dialysis International follows the International Committee of Medical 
Journal Editors’ (ICMJE) Recommendations for the Conduct, Reporting, Editing, and 
Publication of Scholarly Work in Medical Journals, which can be found at 
http://www.icmje.org/. Authors may refer to ICMJE’s “Manuscript Preparation” 
guidelines in addition to the guide- lines provided below.  
GENERAL FORMAT 
Write the body of the manuscript as concisely as possible, adhering to the word 
limits specified for the given manuscript category.  
For section and subsection headings, please use the heading styles built into your 
word processing template.  
LEVEL ONE HEADING  
LEVEL TWO HEADING 
If further divisions of the text are required, use inline headings: 
In-line Heading Level One:  
In-line Heading Level Two:  
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Paragraph text .... Paragraph text .... 
To facilitate the review process, manuscripts must be in Microsoft Word format. 
Double space all text, including references and figure legends, and allow adequate 
margins. Use a common typeface such as Verdana, Arial, Helvetica, or Times in 11 
or 12 points. Special or mathematical characters and Greek letters that are not on a 
standard keyboard must be created by using the Symbol font. Pages should be 
consecutively numbered, beginning with “1” on the title page. 
Focus on the content rather than the look of a submission. Simpler is always better. 
In running text, formatting other than the usual uses of italic, superscript, and 
subscript is discouraged. During the copyediting process all extraneous formatting 
will, in any case, be stripped from the file to ensure smooth intake into the layout 
programme used by the typesetter.  
All papers must contain the following items, when applicable: 
• Title Page








The first page of the manuscript should include: 
1. The Title of the article (80 characters maximum, including spaces);
2. A running title (30 characters maximum, including spaces);
3. The names of the authors (written as first name, initial(s), and
surname). Correct: Jane A. Smith, Paul T. Jones, Theresa Ryan.
Incorrect: J.A. Smith, P. Jones;
4. The affiliation(s) for each author. For each affiliation, include the
name of the department (if any), the institution, the city, the province
or state (if applicable), and the country where the work was done.
Use superscript Arabic numerals to indicate which authors are
associated with which affiliations;
5. Acknowledgements: These include grants, equipment, drugs, and/or
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other support that facilitated conduct of the work described in the 
article or the writing of the article itself; 
6. Full details on any possible previous or duplicate publication of any
content of the paper (if applicable);
7. The name, postal address, and e-mail address of the corresponding
author;
8. The word count for the text only (excluding abstract,
acknowledgments, disclosures, tables figure legends, and
references);
9. The number of figures and tables; and
10. The details of supplemental online material.
ABSTRACT AND KEY WORDS 
For Original Articles, include a structured abstract of no more than 250 words, with 




 Conclusions (or Summary)
For Review Articles, Consensus Statements, Guidelines, and Short Reports, include 
an unstructured abstract of no more than 250 words that summarizes the objective, 
main points, and conclusions of the article. Do not include abstracts for Editorials, 
Commentaries, and Correspondence.  
After the abstract, list up to eight key words or phrases for indexing. The key words 
should be different from those used in the title. A list of key words is required for all 
Original Articles, Review Articles, Consensus Statements, Guidelines, and Short 
Reports. Key words are optional for Correspondence; Commentaries do not have 
key words. Present the key words in one paragraph, separated by semi-colons, with 
a period at the end. Only the first key word should be capitalized.  
TEXT 
Abbreviations and Symbols: 
Use abbreviations sparingly and keep to those commonly used in the field. All 
acronyms and initialisms are to be spelled out on first use in the abstract, the text, 
and in each table or figure, with the abbreviation following in parentheses. If the 
term is repeated less than four times in the text, all instances must be spelled out. 
Abbreviations used in the body of the article should be indicated in the abstract, 
tables and figures, even if they are used only once or twice in these section, spelling 
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out the first instance. 
Do not begin a sentence with an abbreviation. Spell the phrase out in full or rewrite 
the sentence. Do not explain abbreviations for units of measurement [3 mL, not 3 
milliliters (mL)] or standard scientific symbols [Na, not sodium (Na)]. Do abbreviate 
long names of chemical substances and terms for therapeutic combinations, such 
as DNA. Abbreviate names of tests and procedures that are better known by their 
abbreviations than by the full name (VDRL test, SMA-12). Abbreviate units of 
measurement when they appear with numerals (measured in milliliters, but 10 mL). 
Use abbreviations in figures and tables to save space. Explain all abbreviations 
used in the figure legend or table footnote.  
Units of Measurement: Use SI units throughout. When units other than SI units are 
widely used, they can be indicated in parentheses after the SI unit. The editorial 
office will provide conversion information with the article when appropriate.  
Proprietary and Generic Names: Generic names must be used for all drugs. Include 
the proprietary name in the following cases: if it is more commonly known than the 
generic name; to differentiate among drug forms; if a specific trade preparation was 
used in a study or involved in an adverse effect. If the proprietary name is used, the 
name and location of the manufacturer must be given in parentheses in the text. 
Instruments may be referred to by proprietary name; the name and location of the 
manufacturers must be given in parentheses in the text.  
Use of English Language: All papers are published in English, and authors who are 
not fluent in English are advised to seek editorial help before submitting their 
papers. This will help to ensure that the academic content of the paper is fully 
understood by the journal editors and reviewers.  
Original Articles: Introduction, Methods, Results, Discussion, Conclusions, 
Acknowledgments (optional), Disclosures, References, Figure Legends, and Tables. 
Additional descriptive subheadings may be used if appropriate.  
REFERENCES 
References in the text are numbered consecutively using Arabic numerals in 
parentheses. The manuscript’s reference list is numbered consecutively, using 
Arabic numerals, in the order in which the references are first cited in the text. 
Citations appearing in tables and figures must fit into the numbering sequence from 
the point at which the table or figure is first mentioned in the text. PDI’s citation style 
follows the Vancouver style, which should be selected if using reference handling 
software, such as EndNote.  
Do: 
1. Number references in the order in which they are first cited in the text;
2. Use Arabic numerals in parentheses;
3. Use the reference style of the National Library of Medicine, including the
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abbreviations of journal titles, which should be abbreviated according to the 
style used in the list of Journals Indexed for MEDLINE, posted by the NLM 
on the Library’s Web site (http://www.nlm.nih.gov/tsd/serials/lji.html); 
4. Include an “available from” note for documents that may not be readily
accessible;
5. Cite symposium papers only from published proceedings;
6. When citing an article or book accepted for publication but not yet published,
include the title of the journal (or name of the publisher) and the year of
expected publication;
7. When citing an article that has been published online but not yet in print,
include the digital object identifier (doi); and
8. Include references to unpublished material in the text, not in the references
[for example, papers presented orally at a meeting; unpublished work
(personal communications, papers in preparation)] and submit a letter of
permission from the cited persons to cite such communications.
Do not use ibid. or op cit.
TABLES 
Authors are asked to keep each table to a reasonable size; very large tables packed 
with data simply confuse the reader and may be included as Supplemental Material 
(see below). Similarly, try to minimize the use of abbreviations, and if abbreviations 
must be used, use well-known and accepted forms to minimize the need for the 
reader to constantly refer to the table legend. The same data should not be 
presented in both a table and a figure.  
Tables are to be numbered using Arabic numerals in the order in which they are 
cited in the article text. Tables should also have a title (above the table) that 
summarizes the whole table; it should be no longer than 15 words. Every table 
column and row should be provided with an explanatory title stub, with units of 
measure applicable to the row or column clearly indicated.  
Tables must be formatted using the table tool in a word processing programme to 
ensure that columns of data remain aligned when the file is sent electronically for 
review. The table should be formatted with a horizontal line above the column title 
stubs, between the column title stubs and the table body, and at the end of the table 
body. Vertical lines, color, and shading are not to be used; parts of the table can be 
highlighted using symbols or bold text, the meaning of which should be explained in 
the table legend. Tables must not be embedded as figures or spreadsheet files.  
Table legends follow the table body and should be as concise as possible. 
Footnotes follow the table legend and should be indicated using superscripted 
lowercase letters (a, b, c, and so on). Tables (together with their footnotes and 
legends) should be completely intelligible without reference to the text.  
61 
All tables (including their associated title, footnotes, and legends) should appear in 
consecutive numerical order after the references and any figure legends. All tables 
will be placed close to their text citations during article layout. All tables must be 
cited in the article text.  
FIGURES 
Format: Figures for reproduction should approximately fit within the typeset area of 
the journal. The following resolutions are optimal:  
 Black-and-white line drawings, 600–1200 dpi
 Line drawings with some grey or coloured lines, 600 dpi
 Illustrations and photographs, 300 dpi   Authors should supply electronic
versions of the figure content in EPS, GIF, TIFF, or JPEG format. Other
formats, such PDFs, may be used, but are not preferred. Drawings made in
Microsoft Word and PowerPoint are discouraged, because the display of
such drawings varies with the settings of each computer used to view the
file. There is no guarantee that such figures will reproduce exactly as
intended by the author. Save each figure in a separate file without its title or
legend, and use simple file-naming conventions (for example, Figure 1,
Figure 2A).
Figure Legends: Figures are to be numbered using Arabic numerals (1, 2, 3, and so 
on) in the order in which they are cited in the article text. If a figure has several 
panels, each panel should be identified using an uppercase alphabetic character (A, 
B, C, and so on). Each figure should have a title and an explanatory legend that 
clearly identifies the meaning of any symbols, arrows, numbers, or abbreviations 
used in the illustration. The legend should permit the figure to be understood without 
reference to the text.  
Title and legend information for each figure should be included with the article text, 
grouped and placed at the end of the manuscript, after the reference list. All figures 
will be placed close to their text citations during article layout. Make sure that each 
figure is cited in the article text.  
